Immatics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Immatics şirketinin toplam hissedar öz sermayesi €387.9M ve toplam borcu €0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €627.0M ve €239.1M dir.

Anahtar bilgiler

Borç/özkaynak oranı

€0

Borç

Faiz karşılama oranı	n/a
Nakit	€158.14m
Eşitlik	€387.89m
Toplam yükümlülükler	€239.08m
Toplam varlıklar	€626.97m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4A3 'nin kısa vadeli varlıkları ( €559.1M ) kısa vadeli yükümlülüklerini ( €149.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: 4A3 şirketinin kısa vadeli varlıkları ( €559.1M ) uzun vadeli yükümlülüklerini ( €89.5M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4A3 borçsuzdur.

Borcun Azaltılması: 4A3 son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 4A3 şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: 4A3 serbest nakit akışı her yıl % 14.3 1.3 yıl yetecek nakit akışına sahip olacaktır.

Immatics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Immatics N.V. has completed a Follow-on Equity Offering in the amount of $150.3125 million.

Immatics N.V. has filed a Follow-on Equity Offering.

Second quarter 2024 earnings released: €0.17 loss per share (vs €0.32 loss in 2Q 2023)

Immatics N.V. Appoints Alise Reicin to Board of Directors

New major risk - Share price stability

First quarter 2024 earnings released: €0.03 loss per share (vs €0.26 loss in 1Q 2023)

New major risk - Financial position

New major risk - Revenue and earnings growth

Full year 2023 earnings released: €1.20 loss per share (vs €0.56 profit in FY 2022)

Immatics N.V., Annual General Meeting, Jun 19, 2024

Immatics N.V. has completed a Follow-on Equity Offering in the amount of $175.175 million.

Immatics N.V. has filed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

New major risk - Financial position

Immatics N.V. Reports Interim Clinical Data from ACTengine IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRame in an Ongoing Phase 1 Trial

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Immatics N.V. Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine(R) IMA203 TCR-T Monotherapy

New major risk - Share price stability

Immatics N.V. Initiates Phase 1/2 Clinical Trial to Evaluate Promame TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

Immatics N.V., Annual General Meeting, Jun 20, 2023

First quarter 2023 earnings released: €0.26 loss per share (vs €1.36 profit in 1Q 2022)

Investor sentiment improves as stock rises 49%

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: €0.56 (vs €1.48 loss in FY 2021)

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released: €0.32 loss per share (vs €0.43 loss in 3Q 2021)

Immatics Reports Interim Clinical Data Update on Actengine(R) Ima203 Tcr-T Monotherapy Targeting Prame

Investor sentiment deteriorated over the past week

Immatics N.V. Presents Comprehensive Preclinical Data Set for Tcr Bispecific Candidate Ima402 Targeting Prame At European Society for Medical Oncology (Esmo) Congress 2022

Immatics N.V. Announces First Cancer Patient Treated with Second-Generation Actengine(R) Tcr-T Candidate Ima203cd8 Targeting Prame

Second quarter 2022 earnings released: €0.21 loss per share (vs €0.42 loss in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: €1.36 (vs €0.36 loss in 1Q 2021)

Immatics N.V., Annual General Meeting, Jun 13, 2022

Immatics N.V. Announces First Patient Treated with Actengine® Ima203 Tcr-T in Combination with Checkpoint Inhibitor Opdivo® (Nivolumab) in Patients with Advanced Solid Tumors

Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Third quarter 2021 earnings released: €0.43 loss per share (vs €2.61 loss in 3Q 2020)

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin